Employees: 2,903
Size Gufic Biosciences (GUFICBIO.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $452M, the 893rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹422.25 on 18 Nov 2026.
Performance Over six months the shares gained 47.6%, against -21.2% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 16.7% over the last twelve months (peer median +4.9%); the operating margin is 13.6% (peer median 4.3%).
Valuation It trades at 4.3× enterprise value to sales against a peer median of 3.4× (8th most expensive of 19).
Capital Return on invested capital runs 4.4 points above its cost of capital (10.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹9.81B | ₹9.44B | ₹8.20B | ₹8.07B | ₹6.91B |
| Revenue growth | — | +15% | +2% | +17% | — |
| Gross profit | ₹3.57B | ₹2.59B | ₹2.44B | ₹2.41B | ₹2.05B |
| EBITDA | ₹1.65B | ₹1.54B | ₹1.40B | ₹1.50B | ₹1.40B |
| Net income | ₹735M | ₹642M | ₹696M | ₹861M | ₹797M |
| Free cash flow | n/a | -₹178M | ₹271M | -₹1.32B | -₹2.20B |
| Capital expenditure | n/a | ₹312M | ₹755M | ₹1.13B | ₹1.88B |
| Total debt | n/a | ₹4.05B | ₹3.36B | ₹3.33B | ₹3.34B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GUFICBIO.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.4% | -11.0% | 4th highest of 21 |
| 6-month return | +47.6% | -21.2% | 2nd highest of 20 |
| Distance from 52-week high | -14.5% | -41.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +16.7% | +4.9% | 7th highest of 20 |
| Operating margin | 13.6% | 4.3% | 6th highest of 19 |
| EV / Sales | 4.3× | 3.4× | 8th most expensive of 19 |
| ROIC minus cost of capital | +4.4 pp | -2.2 pp | 5th highest of 19 |
| EV / EBITDA | 25.6× | 25.9× | 2nd cheapest of 4 |
| Net debt / EBITDA | 2.0× | 0.9× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gufic Biosciences GUFICBIO.NS | India | $452M | +48% | +17% | 14% | 4.3× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $449M | -21% | -9% | 5% | 2.4× | 4.5% | +3.3% |
| Dong-A Socio 000640.KS | South Korea | $447M | -8% | +11% | 7% | 0.7× | -6.6% | +12.8% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $445M | -21% | +5% | 19% | 3.4× | 1.3% | +1.3% |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | 2.2× | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $443M | +10% | +15% | 17% | 5.3× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $441M | -25% | -14% | 0% | 0.2× | -9.9% | -3.4% |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | 10.8× | 44.1% | +1.0% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | 4.2× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | 2.1× | -5.6% | -5.6% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | 10.6× | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | 7.2× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | 8.8× | n/a | n/a |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 1.8× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 16.6× | 24.8% | +126.7% |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 2.9× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 1.1× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 3.4× | -0.2% | +14.5% |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |